Haseeb Ahmad – Country President, Novartis UK
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Address: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Camberley, Surrey, GU16 7SR, United Kingdom
Tel: +44 (0)1276 692255
Web: http://www.novartis.co.uk/index.shtml
Novartis UK is the UK affiliate of Swiss based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world. This pioneering and innovative company came about through the merger, in 1996, of two key Swiss pharmaceutical organisations, Ciba Geigy and Sandoz.
Headquartered in Basel, Novartis employs nearly 100,000 people worldwide and has a presence in over 140 countries. Novartis has a well-earned reputation for introducing innovative and effective medicines for disease areas in need of new therapies – particularly in oncology, transplantation and ophthalmology. The company is also known for producing new and ever-more efficient medicines for the more common cardiovascular and respiratory diseases, as well as for diseases affecting the brain.
Novartis currently has a total of 145 development projects in various stages of clinical development, including potential new products and potential new indications or formulations for existing products.
x Cardiovascular and Metabolism
x Hypertension, Diabetes, Atherosclerosis
x Integrated Speciality Medicines
x Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergies
x Infectious diseases, Transplantation and Immunology
x Organ transplants
x Neuroscience
x Alzheimer’s, Parkinson’s, Epilepsy, Multiple sclerosis
x Ophthalmics
x Age-related macular degeneration, Dry eye Haematologic and solid tumour diseases
Novartis Oncology aims to improve and extend the lives of patients with cancer. It has a wide range of therapy areas, and a broad pipeline of new products and new indications.
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
First published in the November 2025 edition of DIA’s Global Forum, this piece by Jane Morrin O’Rourke, Naho Yamazaki, Becky Purvis (HRA) and Mandy Budwal-Jagait, Jason Wakelin-Smith and Kingyin Lee…
Originally published in the October 2025 edition of DIA’s Global Forum magazine, this article — authored by Mandy Budwal-Jagait, Kingyin Lee, Maria Urdaneta-Abate, Hedwig Ganguly, Rachel Mead, and Louisa Obillo…
As chief development officer of Moderna, Dr Melanie Ivarsson OBE spearheaded the rapid development of a COVID-19 vaccine that helped the world emerge from the pandemic. Now back in the…
Writing in the September 2025 edition of DIA’s Global Forum magazine, Janet Messer, Catherine Blewett, and Naho Yamazaki of the UK Health Research Authority (HRA) and Stephen Lam, Crina Cacou,…
Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France…
The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and…
Writing in the July 2025 edition of DIA Global Forum, Samantha Holmes, Fiona Adshead, and Keith Moore of the Sustainable Healthcare Coalition explore how cross-sector partnerships are advancing environmental sustainability…
Lenny Shallcross, Executive Director of the World Dementia Council, reflects on the evolving global response to Alzheimer’s disease and dementia; from the slow but significant rollout of disease-modifying treatments to…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine…
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including…
See our Cookie Privacy Policy Here
